On Nov 9, 2021 Arbor Biotechnologies closed a Series B round and raised $215,000,000 from Ally Bridge Group, ARCH Venture Partners, ArrowMark Partners, Deep Track Capital, GreatPoint Ventures, Illumina Ventures, Janus Henderson Investors, Logos Capital, Ono Venture Investment, Piper Sandler, Ridgeback Capital, Section 32, Surveyor Capital, T. Rowe Price, Tao Capital Partners, TCG Crossover, Tekla Capital Management, Temasek Holdings, Vertex Pharmaceuticals, Woodline Partners, featuring lead investors Ally Bridge Group, TCG Crossover, Temasek Holdings.
About the company: Arbor Biotechnologies is located at United States, North America.
“Arbor Biotechnologies is an early stage life sciences company pushing the
boundaries of biodiscovery. Using artificial intelligence, genome
sequencing, gene synthesis and high-throughput screening, we are
accelerating the discovery of proteins for improving human health and
sustainability.”
Company website: http://www.arbor.bio
